Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections
Nathaniel Warner, Luther A. Bartelt, Anne M. Lachiewicz, Kathleen Tompkins, Melissa B. Miller, Kevin Alby, Melissa B. Jones, Amy Carr, Jose Alexander, Andrew B. Gainey, Robert Daniels, Anna‐Kathryn Burch, David E. Brown, Michael Brownstein, Faiqa Cheema, Kristin E. Linder, Ryan K. Shields, Sarah Longworth, David van Duin
Abstract
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
Topics & Concepts
Achromobacter xylosoxidansCystic fibrosisMedicineAchromobacterIntensive care medicineInternal medicinePseudomonasBacteriaBiologyGeneticsInfections and bacterial resistanceCystic Fibrosis Research AdvancesAntibiotic Resistance in Bacteria